Published • loading... • Updated
Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
- Pfizer CEO Albert Bourla is shifting focus from COVID vaccines to cancer and obesity treatments amid financial challenges.
- Expectations for continuing vaccine sales have declined, causing Pfizer's stock to drop to about half its peak value.
- Bourla's response includes a $3.5 billion cost-cutting initiative and new drug investments for cancer and obesity.
Insights by Ground AI
16 Articles
16 Articles
Associated Press News+14 Reposted by 14 other sources
Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
WASHINGTON (AP) — Two years ago, Pfizer was the envy of the pharmaceutical world, with more than $100 billion in annual sales from its COVID-19 vaccine and antiviral Paxlovid. Today, CEO Albert Bourla is trying to turn the page from that success story, which has turned into more of a financial headache for the global […]
·New York, United States
Read Full Article
Pfizer moves beyond COVID vaccines to become leader in cancer, obesity treatments
Two years ago, Pfizer was the envy of the pharmaceutical world, with more than $100 billion in annual sales from its COVID-19 vaccine and antiviral Paxlovid. The post Pfizer moves beyond COVID vaccines to become leader in cancer, obesity treatments first appeared on The Journal Record.
Coverage Details
Total News Sources16
Leaning Left5Leaning Right0Center9Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 36%
C 64%
Factuality
To view factuality data please Upgrade to Premium
